Elanco Animal Health Incorporated (NYSE: ELAN) today announced its latest entry into the rapidly growing canine dermatology ...
Johnson & Johnson (NYSE:JNJ) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 26, Johnson & ...
Johnson & Johnson has discontinued a mid-stage trial of its experimental drug for moderate to severe atopic dermatitis after ...
Johnson & Johnson said on Friday it discontinued a mid-stage study of its experimental drug to treat patients with moderate ...
A new study published in the journal of Inflammopharmacology showed that in individuals with moderate-to-severe atopic ...
The company said the results of a planned interim analysis met prespecified criteria for early termination of the study. "They did not meet the high-bar efficacy we established for advancing our ...
The top 5 most-read dermatology content of 2025 on AJMC.com included innovative advances from artificial intelligence ...
Stocktwits on MSN
Johnson & Johnson terminates experimental eczema drug study after it fails to show benefit
The drug JNJ-5939 was being evaluated in the treatment of moderate to severe atopic dermatitis in a mid-stage study. ・JNJ, ...
Here are our top highlights from AAD 2025 that include safety of topical JAK inhibitors, climate impacts on skin health, ...
Bevacizumab has been sold as Avastin by originator Roche for many years and used by the NHS for various forms of cancer, with ...
A few 2025 trials pointed in the same direction: toward treatments built to modify disease biology and better ways to measure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback